Actinium Pharmaceuticals (ATNM)
NYSE MKT:ATNM

Actinium Pharmaceuticals Stock Analysis & Ratings

ATNM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.41 - $10.30
Previous Close$6.03
Volume47.00
Average Volume (3M)637.85K
Market Cap$133.53M
P/E Ratio-5.0
Beta0.31
Next EarningsAug 09, 2019
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-1.20


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ATNM FAQ

What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $4.41 and its highest was $10.30 in the past 12 months.
    What is Actinium Pharmaceuticals’s market cap?
    Actinium Pharmaceuticals’s market cap is $133.53M.
      What is Actinium Pharmaceuticals’s price target?
      The average price target for Actinium Pharmaceuticals is $30.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $45.00 ,the lowest forecast is $22.00. The average price target represents 408.62% Increase from the current price of $6.03.
        What do analysts say about Actinium Pharmaceuticals?
        Actinium Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Actinium Pharmaceuticals’s upcoming earnings report date?
          Actinium Pharmaceuticals’s upcoming earnings report date is Aug 09, 2019 which is 1015 days ago.
            How were Actinium Pharmaceuticals’s earnings last quarter?
            Actinium Pharmaceuticals released its earnings results on May 10, 2019. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$1.8 by $0.3.
              Is Actinium Pharmaceuticals overvalued?
              According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
                Does Actinium Pharmaceuticals pay dividends?
                Actinium Pharmaceuticals does not currently pay dividends.
                What is Actinium Pharmaceuticals’s EPS estimate?
                Actinium Pharmaceuticals’s EPS estimate is -$0.9.
                  How many shares outstanding does Actinium Pharmaceuticals have?
                  Actinium Pharmaceuticals has 22,140,000 shares outstanding.
                    What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
                    Actinium Pharmaceuticals reported an EPS of -$1.5 in its last earnings report, beating expectations of -$1.8. Following the earnings report the stock price went up 2.857%.
                      Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
                      Among the largest hedge funds holding Actinium Pharmaceuticals’s share is Consonance Capital. It holds Actinium Pharmaceuticals’s shares valued at N/A.

                        ---

                        Actinium Pharmaceuticals Stock Analysis

                        The Actinium Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Actinium Pharmaceuticals

                        Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.

                        ---
                        Similar Stocks
                        Company
                        Price & Change
                        Follow
                        Spectrum Pharmaceuticals
                        Atara Biotherapeutics
                        AbbVie
                        Medpace Holdings
                        Seagen

                        Popular Stocks

                        ---
                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis